Dr Ruth L Light, MD | |
41 Germantown Rd, Danbury, CT 06810-4087 | |
(203) 207-3300 | |
Not Available |
Full Name | Dr Ruth L Light |
---|---|
Gender | Female |
Speciality | Preventive Medicine - Occupational Medicine |
Location | 41 Germantown Rd, Danbury, Connecticut |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1831218486 | NPI | - | NPPES |
2032073300 | Other | CT | TELEPHONE NUMBER |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083X0100X | Preventive Medicine - Occupational Medicine | 038228 (Connecticut) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Ruth L Light, MD 41 Germantown Rd, Danbury, CT 06810-4087 Ph: (203) 207-3300 | Dr Ruth L Light, MD 41 Germantown Rd, Danbury, CT 06810-4087 Ph: (203) 207-3300 |
News Archive
Two mornings a week, a van arrives at the Escondido, Calif., home of Mario Perez and takes him to a new senior center in this northern San Diego County town, where he eats a hot lunch, plays cards and gets physical therapy to help restore the balance he lost after breaking both legs in a fall.
Toshiba America Medical Systems, Inc., an industry leader in magnetic resonance (MR) technology, reached a significant achievement in installing its 800th Vantage 1.5T MR system at Elkview General Hospital in Hobart, Okla. Elkview is using the Vantage system for orthopedic, neuro and abdominal imaging.
Researchers at the Mayo Clinic found they could isolate and culture nanoparticles from filtered homogenates of diseased calcified human cardiovascular tissue. These cultured nano-sized particles were recognized by a DNA-specific dye, incorporated radiolabeled uridine, and after decalcification, appeared via electron microscopy to contain cell walls.
Researchers at the BC Centre for Excellence in HIV/AIDS and Simon Fraser University, in partnership with University of British Columbia and Western University, have developed a novel way for dating "hibernating" HIV strains, in an advancement for HIV cure research in the province.
TSO3 Inc. is pleased to announce that it has filed a final short form prospectus with the securities regulatory authorities in all provinces of Canada with respect to a previously announced public offering of 10,000,000 common shares for gross proceeds to the Company of C$16 million. The prospectus also qualifies for the distribution of 150,000 Common shares sold by Simon Robitaille, one of the Company's founders and Chief Scientific Officer, for gross proceeds of $240,000.
› Verified 2 days ago